Accordingly, our previous study demonstrated that elevated markers of inflammation, hypercoagulability and endothelial function (i.e., thrombomodulin, myeloperoxidase, thrombin–anti-thrombin complex) prior to and after the first dose of DOX chemotherapy were able to predict the early subclinical DOX-induced cardiotoxicity in patients with breast cancer [18]. Here, MPO is linked to breast carcinoma.